Clinical Study

Sex Differences in the Effects of Inhaled Corticosteroids on Weight Gain among Patients with Asthma

Amanda K. Rizk,1,2,3,4 Kim L. Lavoie,1,4,5 Véronique Pepin,1,3,4 Alicia Wright,3,4 and Simon L. Bacon1,3,4,6

1 Centre de Recherche, Hôpital du Sacré-Cœur de Montréal-A University of Montreal Affiliated Hospital, 5400 Boulevard Gouin West, Montreal, QC, Canada H4J 1C5
2 Special Individualized Program, Concordia University, 7141 Sherbrooke Street West, Montreal, QC, Canada H4B 1R6
3 Department of Exercise Science, Concordia University, 7141 Sherbrooke Street West, Montreal, QC, Canada H4B 1R6
4 Montreal Behavioural Medicine Centre, Montreal, QC, Canada
5 Département de Psychologie, Université du Québec à Montréal (UQAM), P.O. Box 8888, Succursale Centre-Ville, Montreal, QC, Canada H3C 3P8
6 Research Centre, Montreal Heart Institute-A University of Montreal Affiliated Hospital, 3600 Rue Bélanger, Montreal, QC, Canada H1T 1C8

Correspondence should be addressed to Simon L. Bacon, simon.bacon@concordia.ca

Received 1 August 2012; Accepted 16 August 2012

Academic Editors: A. M. Boylan, A. P. Comellas, A. Kurdowska, K. Nishimura, and C. C. Witt

Copyright © 2012 Amanda K. Rizk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Studies have shown that asthma and asthma exacerbations are related to body weight and that this relationship might be sex-specific. While oral corticosteroids have been associated with weight gain, little is known about the effect of inhaled corticosteroid (ICS) use on short-term weight gain. The purpose of the present study was to examine whether ICSs would be associated with weight gain among asthmatic patients.

Methods. A total of 180 adult patients with physician-diagnosed asthma provided details of their medical history and demographic information, along with height and weight at baseline and at one year. Weight change was defined as follow-up minus baseline weight. General linear models were used to assess the relationship between ICS dose (fluticasone propionate equivalent) and sex.

Results. Significant main effects of sex (P = .005) and ICS dose (P = .036) and an interaction effect of sex and ICS dose (P = .003) on weight change were observed. Further analysis of the interaction indicated that women had greater weight gain, while men had decreased weight with increased ICS dose.

Conclusions. Findings suggest that ICSs may trigger weight gain in females and highlight the need for studies to confirm this relationship and examine the potential underlying mechanisms.

1. Introduction

One of the main physiological characteristics associated with asthma is chronic airway inflammation, which is usually controlled through the use of inhaled corticosteroids (ICSs) [1]. This medication is commonly prescribed as a preventative treatment to reduce and manage the number of exacerbations experienced by asthmatic patients [1]. With its introduction in 1972, it was created with the intention of minimizing adverse effects normally associated with oral corticosteroids, including decreased bone mineral density, cataracts, ecchymosis, skin atrophy, ocular hypertension, glaucoma, and weight gain, by creating a direct pathway to the lungs thereby decreasing systemic absorption [2]. Despite these intentions, research has revealed that ICS’s bring about some adverse systemic effects while still remaining more systematically efficient and safe compared to their oral counter-parts [1, 3–5]. One adverse effect of oral corticosteroids, which has not been widely assessed with ICS’s in adults, is weight gain.

Worldwide, the prevalence of obesity has more than doubled since 1980 [6]. In 2008, 1.5 billion adults, 20 years of age and older, were overweight. Of these overweight
2. Methods

2.1. Study Participants. Patients in this prospective study were recruited from the asthma outpatient clinic at l’Hôpital du Sacré-Cœur de Montréal from June 2003 to Dec 2006. A total of 801 patients were recruited at baseline, constituting 94% of all eligible patients. Of those patients, 180 (22.5%) returned at one year for a clinically required followup and were reassessed as part of the present substudy. Patients were eligible to participate if they had physician-diagnosed asthma (confirmed by spirometry and/or methacholine challenge), were between the ages of 18 and 75 years, and were fluent in English or French. Patients were ineligible to participate if they had a comorbid disease which conferred greater risk for morbidity than asthma (i.e., COPD, cardiovascular disease, etc.), a primary diagnosis of occupational asthma, the presence of severe psychopathology (e.g., schizophrenia), dementia, substance abuse, or if they were pregnant. More specifically, patients were confirmed as having asthma by chart-documented bronchodilator reversibility in FEV1 specifically, patients were confirmed as having asthma by dementia, substance abuse, or if they were pregnant. More such, it is important to examine whether ICS's could possibly be associated with weight gain in an asthmatic population. In the present study, it was hypothesized that the use of ICS's would result in short-term (one-year) weight gain among patients with asthma. A secondary goal was to investigate the sex-specific nature of this relationship, as it has been suggested that the link between asthma and obesity may be more prevalent among women [11]. As such, it was hypothesized that women with asthma would have a greater weight gain at one year compared to men.

2.3. Measures. Self-reported height and weight values were obtained from the patients to calculate BMI (weight in kg/height in m²). Weight status was classified as normal for patients with a BMI less than 25 kg/m², overweight for patients with a BMI between 25 kg/m² and 29.9 kg/m², or obese for those with a BMI equal to or exceeding 30 kg/m². With respect to ICS use, participants provided details about the frequency and dose of ICS medication. All values were converted to fluticasone propionate equivalents and reported as dose per day. All patients underwent standard pulmonary function testing using standard spirometry in the respiratory laboratory by a trained respiratory technician on the day of the patient’s visit. Rescue medication was withheld for at least 4 hours (but up to 8) prior to testing. Predicted values of FEV₁ and FVC were calculated from reference values for patients less than [17] and greater than [18] 70 years of age, respectively, yielding percentage of the predicted FEV₁ and percentage of the predicted FEV₁/FVC ratio.

2.4. Data Reduction and Analyses

2.4.1. Main Analyses. Weight change was defined as follow-up weight minus baseline weight. General linear models (GLMs) were used to assess the relationship between ICS dose and sex, defined as our independent variables, and weight change, defined as our dependent variable. Covariates were defined a priori based on their potential influence on the expected relationships under investigation and included age, baseline smoking status, change in smoking status, level of education, baseline weight, duration of asthma, use of oral corticosteroids, and baseline FEV₁. All patients with data at 1 year were included in the analyses. All statistical analyses were performed using SAS v9.1 (SAS, Cary) and P < .05 was considered statistically significant.

2.4.2. Missing Data. Our missing data analysis procedures used missing at random (MAR) assumptions, as per Rubin’s rules [19]. We used the PROC MI method of multiple multivariate imputation in SAS. We independently analyzed 5 copies of the data, each with missing values suitably imputed, in the GLM analyses. Using PROC MIANALYZE, we averaged estimates of the variables to give a single mean estimate and adjusted standard errors according to Harrell’s guidelines [20]. Details of the amount of missing data per variables are included in Table 1.

3. Results

Baseline sociodemographic, clinical, and asthma characteristics are presented in Table 1. A total of 61% of the participants were women and had a mean (SD) age of 51(14). The mean ± SD of ICS dose (fluticasone propionate equivalent) was 776 ± 568 μg for women and 716 ± 460 μg for men. Clinical/asthma characteristics are indicative of an asthmatic population from a tertiary care setting: as such, it is unsurprising that ICS doses were generally higher than those found in asthmatic populations followed in primary care [21].
would lose 1.30 kg (95% CI = 500–950 models for women and men, it would appear that for every change at 1 year (Figure 1). Based on separate regression analyses, the same pattern of results was seen if baseline BMI was used instead of weight.

The analyses revealed a significant main effect of sex (β (95% CI) = 4.099 (1.221–6.976), P = .005) and ICS dose (β (95% CI) = .002 (.0001–.004), P = .036), as well as a significant interaction effect of sex and ICS dose (β (95% CI) = −.005 (−.008–−.002), P = .003) on weight change. The interaction effect indicated that for women, increasing ICS dose was associated with greater 1-year weight, while for men, higher ICS dose at baseline predicted lower weight change at 1 year (Figure 1). Based on separate regression models for women and men, it would appear that for every 500 μg of fluticasone equivalent of ICS at baseline, men would lose 1.30 kg (95% CI = −2.84–0.25) of weight at 1 year, whereas women would gain 0.94 kg (95% CI = 0–1.89) of weight. For the combined cohort of women and men, a gain of 1.07 kg (95% CI = .07–2.07) was observed.

To assess the potential causal pathways of this relationship, an analysis of the impact of baseline body weight on 1 year ICS dose was conducted. This analysis revealed no significant main effect of sex (β (95% CI) = 409.65 (−864.21–869.15), P = .995), weight (β (95% CI) = 3.88 (−12.86–3.62), P = .252), nor their interaction (β (95% CI) = 5.21 (−10.81–11.27), P = .965) on ICS dose change. For all analyses, the same pattern of results was seen if baseline BMI was used instead of weight.

4. Discussion

Findings from the current study showed that women taking higher dosages of ICS’s experienced greater increases in weight over the course of one year, with an average gain of 94 kg (2.1 lbs) per year, while men tended to experience a decrease in weight with an increase in ICS dose, with an average loss of 1.3 kg (2.9 lbs) per year. Similar results were obtained in a previous study conducted in asthmatic children. Indeed, Jani et al. [22] found that asthmatic children aged one to twelve years receiving ICS doses above 400 μg/day had an annual increase of .44 kg/m²/year (P = .0003) in BMI compared with those receiving less than 200 μg/day, who showed an increase of .10 kg/m²/year (P = .0003). These results were independent of the type of ICS and inhaler device utilized [22]. This study did not, however, explore sex differences [22]. To our knowledge, no other study has investigated the association between ICS dose and weight gain in an adult population. One study conducted by Hedberg and Rössner did, however, investigate if a relationship exists between body weight and asthma medications in a Swedish population 16–60 years of age (n = 17,912). They found there to be no strong evidence to suggest such a relationship in men or women [23].

Table 1: Patient demographics.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Women</th>
<th>Men</th>
<th>Percentage of missing information (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sociodemographics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yr²</td>
<td>51.4 ± 13.5</td>
<td>48.3 ± 13.5</td>
<td>2 (4)</td>
</tr>
<tr>
<td>White race, % (n)</td>
<td>94 (100)</td>
<td>91 (64)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Education, yr²</td>
<td>12.9 ± 3.4</td>
<td>13.4 ± 3.7</td>
<td>4 (7)</td>
</tr>
<tr>
<td>Employed, % (n)</td>
<td>64 (66)</td>
<td>73 (51)</td>
<td>4 (7)</td>
</tr>
<tr>
<td>Cohabitating, % (n)</td>
<td>65 (67)</td>
<td>70 (49)</td>
<td>4 (7)</td>
</tr>
<tr>
<td>Weight, kg²</td>
<td>67.5 ± 15</td>
<td>87.2 ± 19.3</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Baseline BMI, kg/m²</td>
<td>26 ± 5.4</td>
<td>28.1 ± 6.3</td>
<td>2 (4)</td>
</tr>
<tr>
<td><strong>Pulmonary function</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁, % predicted</td>
<td>78.0 ± 19.5</td>
<td>76.2 ± 21.5</td>
<td>7 (13)</td>
</tr>
<tr>
<td>FVC, % predicted</td>
<td>88.0 ± 16.3</td>
<td>89.0 ± 20.2</td>
<td>8 (14)</td>
</tr>
<tr>
<td>FEV₁/FVC, % predicted</td>
<td>72.6 ± 10.7</td>
<td>69.3 ± 10.1</td>
<td>8 (14)</td>
</tr>
<tr>
<td><strong>Asthma history</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma control (ACQ level)</td>
<td>1.5 ± 1.1</td>
<td>1.4 ± 0.9</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Atopic, % (n)</td>
<td>69 (72)</td>
<td>70 (49)</td>
<td>3 (5)</td>
</tr>
<tr>
<td><strong>Asthma medications</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short-acting β₂-agonists, % (n)</td>
<td>96 (102)</td>
<td>100 (70)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Long-acting β₂-agonists, % (n)</td>
<td>83 (88)</td>
<td>74 (52)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>ICS, % (n)</td>
<td>100 (106)</td>
<td>99 (69)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>ICS dose, μg</td>
<td>776 ± 568</td>
<td>716 ± 460</td>
<td>14 (25)</td>
</tr>
<tr>
<td>Oral corticosteroids, % (n)</td>
<td>13 (14)</td>
<td>6 (4)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Antileukotrienes, % (n)</td>
<td>15 (16)</td>
<td>10 (7)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Antihistinetics, % (n)</td>
<td>25 (27)</td>
<td>14 (10)</td>
<td>2 (4)</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD or % (n, no.).

FEV: forced expiratory volume; FVC: forced vital capacity; ICS: inhaled corticosteroids.

*Used in the multiple imputation process.
Figure 1: Relationship between change in weight (kg) and ICS dose (μg fluticasone equivalent) in women (dashed line) and men (solid line).

Several researchers have explored the obesity-asthma phenomenon and identified this relationship as a sex-specific one, where women with increased BMI’s are at greater risk for asthma than women with lower BMIs [9, 12, 24, 25]. For example, a study conducted by Beckett et al. concluded that weight gain exposes young females to new asthma diagnoses, independent of physical activity [24]. However, this relationship was not observed in young males. In a larger study, Chen and colleagues [25] investigated the relationship between asthma and energy expenditure and concluded that obesity was related to the development of asthma in women but not in men. Once again, physical inactivity measured by energy expenditure did not explain this association [25].

An extensive body of literature suggests a strong correlation between obesity and asthma [9–11, 24, 26]. Though controversial, the current paradigm of directionality for this relationship is that obesity increases the risk of developing asthma [9–11, 24, 25]. There are a number of potential mechanisms that may help explain this directional association [27]. These mechanisms include genetics [28], obesity leading to histological changes within the lung [29], decreased airway caliber as a result of chest restriction [30], and sex hormones being influenced by obesity subsequently increasing the risk of asthma [31, 32]. However, it has also been indirectly proposed that asthma may lead to obesity. For instance, oral corticosteroids have been shown to bring about weight gain through systemic absorption of this medication, thereby suppressing the hypothalamic-pituitary-adrenal (HPA) axis, which in turn brings about weight gain [33]. It is possible that such a pathway may explain the current findings. It has been suggested that when an ICS is taken, 10–40% of the medication reaches the lung and 60–90% is swallowed [34]. This swallowed portion gets absorbed by the gastrointestinal tract and then passes through the liver leaving a fraction bioavailable to reach the systemic circulation [34]. Once in the systemic circulation, unwanted adverse effects may be experienced; furthermore, it has been reported that these effects are dose-dependent [34, 35]. Though we were not able to assess this in the current study, it represents an important avenue for future research and highlights the importance of using appropriate inhaler techniques among asthmatics.

Given the differential weight gain in women compared to men in the current study, it is possible that female hormones may play a role in this relationship. The most compelling evidence that female sex hormones play a role in asthma appears in natural models (i.e., menstrual cycle, pregnancy, and menopause) [14]. Sex differences can actually be observed as early as gestation, where the lung of a female fetus matures more rapidly than that of a male fetus [36]. During childhood, the prevalence of asthma is higher in boys than in girls; a relationship that is reversed once girls reach puberty, a stage when estrogen levels are higher suggesting a possibly etiological role [13, 37]. In addition, asthma symptoms have been shown to subjectively worsen during menstruation [38, 39], although other studies have contradicted this finding [40]. In addition, pregnancy is generally characterized by changes in asthma symptoms, ranging from improvements (i.e., reductions in airway hyperresponsiveness) to a worsening of asthma symptoms [13]. A study conducted by Troisi et al. [41] evaluated the association between hormone replacement therapy (conjugated estrogens) and increased asthma incidence. These investigators found that women who were naturally menopausal and reported never using postmenopausal hormones had a significantly lower risk of incident asthma compared to premenopausal women [41]. Finally, estrogens could act in synergy with leptin, which plays a central role in fat metabolism through the regulation of energy intake and expenditure and is positively correlated with body fat and BMI [42]. Leptin receptors exist in human lung tissue [43] and plasma leptin levels have been observed to be higher in women compared to men, independent of obesity [44]. Cytokines, such as IL-6, IL-1β, and TNF-α, are also involved in metabolism and food intake. TNF-α and IL-1β both modulate the release of leptin, and TNF-α and IL-6 act directly on the hypothalamus by altering the regulation of food intake [45, 46]. These relationships suggest that estrogen (both alone and via interactions with leptin) may play a key role in the pathophysiology of asthma and could perhaps help explain why sex differences were observed in this study. Aside from sex hormones, the fact that men tend to have more muscle mass than fat mass as compared to women may have also contributed to the sex differences observed in this study. In addition, the weight loss experienced by men could have improved asthma control thereby reducing the need for medication use [47].

Several behavioural factors may also help explain sex differences in the relationship between ICS use and weight gain. A study conducted by Sundberg and colleagues [48] comparing sex differences among 470 asthmatic men and women found that women had greater self-reported adherence to ICS’s and tended to have a more positive attitude towards their medication, relative to men. Furthermore, women reported having a higher prevalence of insomnia and day-time sleepiness compared to men, which has been
proposed by some as a potential cause of weight gain [48]. Future studies are needed to clarify sex differences in behavioural factors associated with weight gain and ICS use among asthmatic patients.

4.1. Study Limitations and Strengths. The results of this study need to be interpreted in the context of some limitations. The current study utilized self-report measures of weight and height to calculate BMI. However, data from the National Health and Nutrition Examination Survey (NHANES-III) study suggests that the BMI values derived from self-reported height and weight are highly correlated \((r = .89 \text{ to } .97, P < .001)\) with measured height and weight values in both men and women [49], particularly in individuals under the age of 60, which is well within the average age (i.e., 50 years) of the present sample. A second limitation is that this was a convenience sample, as we only have data on a subset of patients who returned to the clinic for the one-year followup. As a result, our sample population may be somewhat biased in the sense that those who returned would be expected to have the most severe or poorly controlled asthma (as shown in Table 1 in their relatively higher ACQ scores). An example of this is the fact that there was a higher than usual number of people with a prescription of oral corticosteroid (though this was still a relatively low proportion, ca. 10%) and the use of such medications may have had an impact on our main question. To account for this we did adjust for oral corticosteroid use in our analyses. Though this population may not be consistent with a family physician seen population of asthmatics, it may be the most relevant group to examine due to their poor control thereby requiring higher ICS doses, thus making them at potentially higher risk for weight gain. In addition, ICS adherence was not measured in this study, which may have influenced the overall weight changes observed in the present study, and the relative weight gain observed in men versus women if adherence differed by sex. In general, asthma patients tend to show poor adherence to ICS’s [50–52]. Given that we found that increased prescribed doses of ICS’s were associated with increased weight gain in women, if patients were less adherent to their medications, this would suggest that our results would, at worst, reflect an underestimation of the effects of ICS on body mass. In addition, a study by Ip et al. [4] found that asthma patients (women in particular) receiving long-term ICS’s had significant decreases in bone mineral density, leading to decreases in body mass. If ICS’s bring about weight gain, but also weight loss due to a loss of bone mineral density in women, this could further underestimate our results. Future studies need to assess not only the relationship between the prescribed doses of ICS medication, but also patient adherence to ICS’s, in order to further elucidate potential causal mechanisms.

Another limitation of our study is that we were unable to acquire data on diet or physical activity levels, which was largely due to the desire to minimize patient assessment burden. However, given the observational nature of this study, it is unlikely that a significant enough change in these complex health behaviours would have likely influenced our results. We were also unable to assess hormonal status in women which has been proposed as a potential mediating factor in the BMI-asthma relationship [53]. Given that this study focused on patients treated in tertiary care, this study may not be generalizable to patients treated in primary care or community samples. However, given that our sample was comprised primarily of moderate-severe asthmatics who tend to receive the highest doses of ICS’s, our focus on tertiary care asthmatics may also be viewed as appropriate and a strength, as weight gain may be relevant to this subpopulation of asthmatics due to their needs for higher doses of ICS’s. Finally, as we only assessed weight change and not actual body fat, it is possible that the changes we observed reflected increases in muscle mass and not increases in adiposity. However, previous studies have shown that yearly increases in body weight in middle-aged individuals are generally driven by increases in fat mass rather than fat-free mass [54]. Future studies are needed to assess if this is also true of patients taking ICS’s.

Despite some limitations, this study also has a number of important strengths. Such strengths include the use of a prospective study design as well as a well-characterized sample of moderate to severe asthmatics whose diagnoses were objectively confirmed. We assessed sex differences and included the statistical control of important covariates such as smoking cessation in our main analyses. Additionally, we used multiple imputation to deal with missing data, resulting in a complete dataset for all participants. These novel and perhaps provocative findings may stimulate future research and further inform the asthma-obesity literature.

4.2. Clinical Relevance. The consequences of obesity are serious as this condition has a profound impact on morbidity and mortality rates and is associated with other diseases states [7]. Though mechanistic studies and replications are needed, our results suggest that higher ICS doses bring about weight gain in female patients with asthma. A study conducted by Sun et al. [55] found that for every 1 unit increase of BMI, there was a 12% reduction of the odds of healthy survival. Additionally, they found that for every 1 kg increase in weight gain since the age of 18, the odds of healthy survival in women decrease by 5% [55]. Given that weight gain is a concern for many patients [56], particularly women, intervening and providing help with weight control and management may encourage more patients to adhere to their medication regimen and improve asthma outcomes [57]. Applying a preventative approach to weight gain can be accomplished through referral to exercise specialists, dieticians/nutritionists, or behavioural weight management counsellors. Future studies are necessary to investigate if such an intervention can alter the potential ICS-weight gain relationship. Furthermore, given the finding that higher ICS use in men was associated with weight loss, further research is needed to explore the reasons for and potential clinical utility of this finding.

5. Conclusion

In a sample of 180 asthmatic patients, higher ICS doses were associated with an increase in body weight at one
year in women and with a decreased weight in men. These findings suggest a temporal association between asthma and increased body weight among women and points to the possible role of ICS medication use. Further research is needed to clarify the extent to which this relationship is influenced by sex hormones, dietary and exercise behaviours, and medication adherence, in order to further elucidate possible mechanisms.

**Abbreviations**

ICS: Inhaled corticosteroids  
BMI: Body mass index  
CI: Confidence interval.

**Acknowledgments**

The authors thank Mr. Guillaume Lacoste for his invaluable assistance in patient recruitment. Funding support for this study was provided by the Social Sciences and Humanities Research Counsel of Canada (SSHRC), the Fonds de la recherche en santé du Québec (FRSQ), and the Fondation de l'Hôpital du Sacré-Cœur de Montréal. Individual funding was provided by FRSQ (SLB, KLL, VP), and the Canadian Institute of Health Research (CIHR) (SLB). As well, scholarship support was provided by CIHR (AW), and the Quebec Respiratory Health Training Program (QRHTP) (AKR) sponsored by CIHR and FRSQ.

**References**


